Optimization of Fermentation and Purification Processes for the Production of Linear Covalently Closed DNA Ministrings

线性共价闭合 DNA 小串生产的发酵和纯化工艺优化

• 批准号: 522225-2017
• 负责人: Sheikhzadeh, Mehdi
• 金额: $ 1.82万
• 依托单位: Lambton College of Applied Arts and Technology
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 1
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=664969
• 关键词: Optimization; Fermentation; Purification; Processes; Production

Safer DNA vectors with high stability, efficacy and efficient purification are of high demand in the gene therapy (GT) industry as a delivery device for genetic cargo. To date, while many vector approaches have been applied to GT, they have fallen short in vector expression delivery, duration and gene expression efficiency, and safety.** **Mediphage Bioceuticals, a start-up company that utilizes bacteriophage and/or bacteriophage elements to develop platform technologies for gene therapeutics is partnering with Lambton College's Bio-industrial Process Research centre is to optimize a fermentation and purification process for the production of linear covalently closed DNA minivectors.****The Lambton College research team that will work closely with Mediphage Bioceuticals includes a principal investigator and two research students. The results of the project will relieve the msDNA production bottleneck and provide an efficacious and safe approach to cell engineering, as well as ensure a stable and inexpensive supply of vector to enable new cell and gene therapies.****

具有高稳定性、有效性和高效纯化的更安全的DNA载体作为遗传货物的递送装置在基因治疗（GT）工业中具有很高的需求。迄今为止，虽然许多载体方法已应用于GT，但它们在载体表达递送、持续时间和基因表达效率以及安全性方面都存在不足。**Mediphage Bioceuticals是一家利用噬菌体和/或噬菌体元件开发基因治疗平台技术的初创公司，该公司与兰顿学院的生物工业过程研究中心合作，优化发酵和纯化过程，以生产线性共价闭合的DNA微载体。*将与Mediphage Bioceuticals密切合作的兰顿学院研究团队包括一名首席研究员和两名研究生。该项目的结果将缓解msDNA生产瓶颈，为细胞工程提供有效和安全的方法，并确保稳定和廉价的载体供应，以实现新的细胞和基因疗法。